Cohort characteristics
| TA314 does not advise ICD (n=707) | TA314 advises ICD (n=319) | p value | |
|---|---|---|---|
| Age (years) | 66.9 (0.5) | 70.6 (0.6) | <0.001 |
| Heart rate (bpm) | 75 (0.8) | 74.2 (1) | 0.52 |
| Systolic BP (mmHg) | 123 (0.8) | 116.8 (1.2) | <0.001 |
| QRS interval (ms) | 110.6 (1) | 152.2 (1.3) | <0.001 |
| Haemoglobin (g/l) | 136 (1) | 135 (1) | 0.38 |
| eGFR (ml/Kg/1.73m2) | 56.2 (0.7) | 53.2 (0.9) | 0.008 |
| LVEDD (mm) | 56.2 (0.3) | 62.9 (0.5) | <0.001 |
| LVEF (%) | 34.7 (0.3) | 26.3 (0.4) | <0.001 |
| Ramipril dose (mg/day) | 5 (0.1) | 4.9 (0.2) | 0.73 |
| Bisoprolol dose (mg/day) | 3.8 (0.1) | 3.3 (0.2) | 0.038 |
| Furosemide dose (mg/day) | 51.6 (1.9) | 57.4 (2.9) | 0.094 |
| Diabetes (% (n)) | 28.6 (202) | 19.7 (63) | 0.003 |
| Ischaemic aetiology (% (n)) | 63.6 (450) | 59.9 (191) | 0.25 |
| CRT (% (n)) | 14.6 (103) | 56.4 (180) | <0.001 |
| ICD (% (n)) | 9.2 (65) | 23.5 (75) | <0.001 |
| NYHA class (% (n)) | <0.001 | ||
| 1 | 22.8 (161) | 16.6 (53) | |
| 2 | 48.4 (342) | 41.1 (131) | |
| 3 | 26.4 (187) | 42.3 (135) | |
| 4 | 2.4 (17) | 0 | |
| ACEi / ARB use (% (n)) | 88.2 (623) | 88.6 (280) | 0.87 |
| Betablocker use (% (n)) | 82 (579) | 79.7 (252) | 0.39 |
| MRA use (% (n)) | 38.8 (274) | 47.5 (150) | 0.009 |
CRT, cardiac resynchronisation therapy; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter defibrillator; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York heart association.